Last reviewed · How we verify
OROS MPH Tablets
OROS MPH is an extended-release formulation of methylphenidate that provides sustained dopamine and norepinephrine reuptake inhibition throughout the day.
OROS MPH is an extended-release formulation of methylphenidate that provides sustained dopamine and norepinephrine reuptake inhibition throughout the day. Used for Attention deficit hyperactivity disorder (ADHD) in children and adults.
At a glance
| Generic name | OROS MPH Tablets |
|---|---|
| Sponsor | Ortho-McNeil Janssen Scientific Affairs, LLC |
| Drug class | Central nervous system stimulant; dopamine-norepinephrine reuptake inhibitor |
| Target | Dopamine transporter (DAT); norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Methylphenidate is a central nervous system stimulant that blocks the reuptake of dopamine and norepinephrine at the presynaptic neuron, increasing their availability in the synaptic cleft. The OROS (osmotic release oral system) delivery technology uses osmotic pressure to gradually release methylphenidate over 8-12 hours, providing consistent therapeutic levels and reducing the need for multiple daily doses. This mechanism enhances attention, focus, and impulse control in patients with attention deficit hyperactivity disorder.
Approved indications
- Attention deficit hyperactivity disorder (ADHD) in children and adults
Common side effects
- Insomnia
- Decreased appetite
- Headache
- Nervousness or anxiety
- Abdominal pain
- Tachycardia
- Elevated blood pressure
Key clinical trials
- Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) (PHASE4)
- Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 (PHASE3)
- Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD) (PHASE3)
- An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD) (PHASE4)
- Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD) (PHASE4)
- CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults (PHASE3)
- An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OROS MPH Tablets CI brief — competitive landscape report
- OROS MPH Tablets updates RSS · CI watch RSS
- Ortho-McNeil Janssen Scientific Affairs, LLC portfolio CI